Logo

NCI Purchases Illumina BeadLab for Cancer Genotyping Studies

Sep 01, 2005

NEW YORK, Sept. 1 (GenomeWeb News) - The National Cancer Institute has purchased genotyping instrumentation from Illumina for its Advanced Technology Center core genotyping facility in Gaithersburg, Md., the company said today.

 

The facility plans to use the BeadLab station initially for research into the genetics of breast and prostate cancer and will support the NCI's Cancer Genetic Markers of Susceptibility initiative.

 

NCI researchers plan to genotype approximately 15,000 loci for each of more than 6,000 DNA samples. Later, they want to develop a pool of 1,536 SNP assays associated with prostate cancer and genotype over 15,000 samples to validate a set of biomarkers for prostate cancer.

 

Illumina has already been providing genotyping services for the NCI's SNP500 cancer project.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.